Although a decent overview, this article is very limited in its coverage and does little to balance the limitations. Although the paper does suggest anti-lag3 therapies could be viable targets in PD, it is a jump to say that an "FDA approved treatment already exists". The FDA drug in question "nivolumab/relatlimab", was not actually used in the original publication, instead a differing lag3 targeting antibody was used. However the article erroneously claims the nivoluman/relatlimab molecule was originally used. Limitations on the translatability of findings from mouse to human are not accounted for or mentioned.